Degarelix
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Degarelix and local guidelines before prescribing.
GnRH antagonist
Mechanism
GnRH antagonist.
Uses
Advanced hormone-dependent prostate cancer.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hot flushes, injection-site reactions, QT prolongation.
Interactions
QT-prolonging drugs.
Contraindications and cautions
Hypersensitivity
Monitoring
PSA, ECG
Pregnancy and breastfeeding
Not applicable
Renal and hepatic impairment
Caution in severe renal and hepatic impairment
Overdose and reversal
Supportive
Special advice
No testosterone flare.
More from the textbook: uses, cautions and other points
- GnRH agonists (goserelin, leuprorelin, triptorelin) - prostate and breast cancer, endometriosis, fibroids, precocious puberty; initial testosterone flare (cover with an anti-androgen such as bicalutamide in prostate cancer - can cause cord compression or urinary obstruction otherwise); then hot flushes, osteoporosis, loss of libido. …
Endocrine: Anatomy Physiology and Pharmacology - LHRH antagonists (degarelix, relugolix) - no flare.
Oncology: Principles - Degarelix / relugolix | GnRH antagonists - no flare.
Oncology: Urology and Genital cancers
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (1 mention)
- Oncology: Principles (1 mention)
- Oncology: Urology and Genital cancers (1 mention)